TWiV 1041: Novel oral polio vaccine? with Raul Andino and Kostya Chumakov
Vincent speaks with Raul and Kostya about the development of novel oral polio vaccine from the Sabin type 2 strain, its deployment in over 600 million children, and whether it can lead to eradication ...
3 Syys 20231h 29min
TWiV 1040: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the public health significance of finding autochthonous melioidosis cases in the continental United States, human neural larva migrans caused by Op...
2 Syys 202348min
TWiV 1039: Landmines for phages, a mouthful of redondoviruses
TWiV describes how a viral capsid protein activates a bacterial innate immune system that interferes with protein synthesis, and human-associated redondoviruses that infect the commensal protozoan Ent...
27 Elo 20232h 1min
TWiV 1038: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, pr...
26 Elo 202326min
TWiV 1037: Antibodies, the good (CoV), the bad (Ad), the beautiful
TWiV reviews evidence that symptomatic adenovirus infection leads to thrombocytopenia, thrombosis, and production of anti-platelet factor 4 antibodies similar to the rare disorder seen after immunizat...
20 Elo 20231h 55min
TWiV 1036: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infecti...
19 Elo 202340min
TWiV 1035: Poxvirus wars, warp speed COVID-19 vaccine rollout
TWiV dissects a study of COVID-19 vaccination which shows that the timing of initial rollout affects disease outcomes more substantially than final coverage or degree of socioeconomic disparity, and d...
13 Elo 20232h
TWiV 1034: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate, associati...
12 Elo 202337min
